BEAM vs CRSP
BEAM and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $2.62B | $4.63B |
| P/B | 2.25 | — |
| P/S | 18.8x | 1317.7x |
| Revenue | $164.01M(TTM) | — |
| Revenue growth (YoY) | 120.0% | -90.6% |
| Net income | -$65.98M(TTM) | — |
| Earnings growth (YoY) | 78.8% | -58.8% |
| EPS, diluted | $-0.49(TTM) | — |
| EBIT margin | -274.6% | -18933.6% |
| ROE | -6.9% | -32.1% |
| ROIC | -39.3% | -33.6% |
| 1y total return | +29.3% | -14.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs CRSP
| Metric | BEAM | CRSP |
|---|---|---|
| End value | $13.6K | $8.8K |
| Total return | +36.1% | -11.7% |
| CAGR | +4.9% | -1.9% |
| Volatility | 80.1% | 61.8% |
| Sharpe | 0.41 | 0.21 |
| Sortino | 0.62 | 0.32 |
| Max drawdown | -89.1% | -85.1% |
Based on 1629 common trading days, 2020-02-06 → 2026-07-31 · risk-free 3.83% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)